European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors

Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII
Source: Roche Media News - Category: Pharmaceuticals Source Type: news